These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 27196777)
1. NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer. Li LS; Reddy S; Lin ZH; Liu S; Park H; Chun SG; Bornmann WG; Thibodeaux J; Yan J; Chakrabarti G; Xie XJ; Sumer BD; Boothman DA; Yordy JS Mol Cancer Ther; 2016 Jul; 15(7):1757-67. PubMed ID: 27196777 [TBL] [Abstract][Full Text] [Related]
2. NQO1-dependent, Tumor-selective Radiosensitization of Non-small Cell Lung Cancers. Motea EA; Huang X; Singh N; Kilgore JA; Williams NS; Xie XJ; Gerber DE; Beg MS; Bey EA; Boothman DA Clin Cancer Res; 2019 Apr; 25(8):2601-2609. PubMed ID: 30617135 [TBL] [Abstract][Full Text] [Related]
3. Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers. Cao L; Li LS; Spruell C; Xiao L; Chakrabarti G; Bey EA; Reinicke KE; Srougi MC; Moore Z; Dong Y; Vo P; Kabbani W; Yang CR; Wang X; Fattah F; Morales JC; Motea EA; Bornmann WG; Yordy JS; Boothman DA Antioxid Redox Signal; 2014 Jul; 21(2):237-50. PubMed ID: 24512128 [TBL] [Abstract][Full Text] [Related]
4. Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone. Chakrabarti G; Silvers MA; Ilcheva M; Liu Y; Moore ZR; Luo X; Gao J; Anderson G; Liu L; Sarode V; Gerber DE; Burma S; DeBerardinis RJ; Gerson SL; Boothman DA Sci Rep; 2015 Nov; 5():17066. PubMed ID: 26602448 [TBL] [Abstract][Full Text] [Related]
5. Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers. Bey EA; Reinicke KE; Srougi MC; Varnes M; Anderson VE; Pink JJ; Li LS; Patel M; Cao L; Moore Z; Rommel A; Boatman M; Lewis C; Euhus DM; Bornmann WG; Buchsbaum DJ; Spitz DR; Gao J; Boothman DA Mol Cancer Ther; 2013 Oct; 12(10):2110-20. PubMed ID: 23883585 [TBL] [Abstract][Full Text] [Related]
6. Susceptibility of cancer cells to beta-lapachone is enhanced by ionizing radiation. Park HJ; Ahn KJ; Ahn SD; Choi E; Lee SW; Williams B; Kim EJ; Griffin R; Bey EA; Bornmann WG; Gao J; Park HJ; Boothman DA; Song CW Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):212-9. PubMed ID: 15629614 [TBL] [Abstract][Full Text] [Related]
7. β-lapachone significantly increases the effect of ionizing radiation to cause mitochondrial apoptosis via JNK activation in cancer cells. Park MT; Song MJ; Lee H; Oh ET; Choi BH; Jeong SY; Choi EK; Park HJ PLoS One; 2011; 6(10):e25976. PubMed ID: 21998736 [TBL] [Abstract][Full Text] [Related]
8. NAD(P)H:quinone oxidoreductase 1 determines radiosensitivity of triple negative breast cancer cells and is controlled by long non-coding RNA NEAT1. Lin LC; Lee HT; Chien PJ; Huang YH; Chang MY; Lee YC; Chang WW Int J Med Sci; 2020; 17(14):2214-2224. PubMed ID: 32922184 [TBL] [Abstract][Full Text] [Related]
9. Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy. Li LS; Bey EA; Dong Y; Meng J; Patra B; Yan J; Xie XJ; Brekken RA; Barnett CC; Bornmann WG; Gao J; Boothman DA Clin Cancer Res; 2011 Jan; 17(2):275-85. PubMed ID: 21224367 [TBL] [Abstract][Full Text] [Related]
10. Beta-lapachone suppresses radiation-induced activation of nuclear factor-kappaB. Dong GZ; Oh ET; Lee H; Park MT; Song CW; Park HJ Exp Mol Med; 2010 May; 42(5):327-34. PubMed ID: 20200474 [TBL] [Abstract][Full Text] [Related]
11. An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis. Huang X; Dong Y; Bey EA; Kilgore JA; Bair JS; Li LS; Patel M; Parkinson EI; Wang Y; Williams NS; Gao J; Hergenrother PJ; Boothman DA Cancer Res; 2012 Jun; 72(12):3038-47. PubMed ID: 22532167 [TBL] [Abstract][Full Text] [Related]
12. β-Lapachone promotes the recruitment and polarization of tumor-associated neutrophils (TANs) toward an antitumor (N1) phenotype in NQO1-positive cancers. Tumbath S; Jiang L; Li X; Zhang T; Zahid KR; Zhao Y; Zhou H; Yin Z; Lu T; Jiang S; Chen Y; Chen X; Fu YX; Huang X Oncoimmunology; 2024; 13(1):2363000. PubMed ID: 38846085 [TBL] [Abstract][Full Text] [Related]
13. Upregulation of NAD(P)H:quinone oxidoreductase by radiation potentiates the effect of bioreductive beta-lapachone on cancer cells. Choi EK; Terai K; Ji IM; Kook YH; Park KH; Oh ET; Griffin RJ; Lim BU; Kim JS; Lee DS; Boothman DA; Loren M; Song CW; Park HJ Neoplasia; 2007 Aug; 9(8):634-42. PubMed ID: 17786182 [TBL] [Abstract][Full Text] [Related]
14. NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by β-lapachone. Moore Z; Chakrabarti G; Luo X; Ali A; Hu Z; Fattah FJ; Vemireddy R; DeBerardinis RJ; Brekken RA; Boothman DA Cell Death Dis; 2015 Jan; 6(1):e1599. PubMed ID: 25590809 [TBL] [Abstract][Full Text] [Related]
15. Prostate cancer radiosensitization through poly(ADP-Ribose) polymerase-1 hyperactivation. Dong Y; Bey EA; Li LS; Kabbani W; Yan J; Xie XJ; Hsieh JT; Gao J; Boothman DA Cancer Res; 2010 Oct; 70(20):8088-96. PubMed ID: 20940411 [TBL] [Abstract][Full Text] [Related]
16. Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors. Huang X; Motea EA; Moore ZR; Yao J; Dong Y; Chakrabarti G; Kilgore JA; Silvers MA; Patidar PL; Cholka A; Fattah F; Cha Y; Anderson GG; Kusko R; Peyton M; Yan J; Xie XJ; Sarode V; Williams NS; Minna JD; Beg M; Gerber DE; Bey EA; Boothman DA Cancer Cell; 2016 Dec; 30(6):940-952. PubMed ID: 27960087 [TBL] [Abstract][Full Text] [Related]
17. Albumin binding revitalizes NQO1 bioactivatable drugs as novel therapeutics for pancreatic cancer. Dou L; Liu H; Wang K; Liu J; Liu L; Ye J; Wang R; Deng H; Qian F J Control Release; 2022 Sep; 349():876-889. PubMed ID: 35907592 [TBL] [Abstract][Full Text] [Related]
18. Cellular and molecular responses to topoisomerase I poisons. Exploiting synergy for improved radiotherapy. Miyamoto S; Huang TT; Wuerzberger-Davis S; Bornmann WG; Pink JJ; Tagliarino C; Kinsella TJ; Boothman DA Ann N Y Acad Sci; 2000; 922():274-92. PubMed ID: 11193903 [TBL] [Abstract][Full Text] [Related]
19. The NQO1 bioactivatable drug, β-lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism. Silvers MA; Deja S; Singh N; Egnatchik RA; Sudderth J; Luo X; Beg MS; Burgess SC; DeBerardinis RJ; Boothman DA; Merritt ME J Biol Chem; 2017 Nov; 292(44):18203-18216. PubMed ID: 28916726 [TBL] [Abstract][Full Text] [Related]
20. PCNA inhibition enhances the cytotoxicity of β-lapachone in NQO1-Positive cancer cells by augmentation of oxidative stress-induced DNA damage. Su X; Wang J; Jiang L; Chen Y; Lu T; Mendonca MS; Huang X Cancer Lett; 2021 Oct; 519():304-314. PubMed ID: 34329742 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]